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Weekly chronomodulated 48 h infusion of high- 
dose 5-fluorouracil modulated by methotrexate 
and (6S)-leucovorin in advanced colorectal 
cancer: a phase IB study
CJA Punt, YL Kamm and DJTh Wagener
Department of Medical Oncology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The 
Netherlands. Tel: (+31) 24 3615215; Fax: (-1-31) 24 3540788.
In th is phase IB study, 24 patients w ith advanced colorectal 
cancer were treated w ith  escalating doses of weekly 
chronomodulated 48 h in fusions of 5-fluorouracll (5-FU) 
biochemically modulated by methotrexate 40 m g/m 2 and 
(6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery 
periods (PDP), during which 65% o f the daily dose was 
administered, were investigated: from 18.00 to 0.30 h and 
from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU 
was 2800 m g/m 2/48 h, w ith a PDP from 18.00 to 0.30 h.
may perm it a fu r th e r  increase in close intensity 
com pared  w ith  delivery at a fiat rate and this has
been  dem onstra ted  in several clinical trials. 11 — 17 In a
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A steep  dose relationship  has been  dem onstra ted  for 
the an titum or efficacy of 5-fluorouracil (5-FU) in 
colorectal cancer . 1 Infusional adm inistration of 5-FU
random ized  trial involving 92 colorectal cancer pa­
tients, the  delivery o f chronom odulated  oxaliplatin, 
5-FU and leucovorin  (LV) w as show n to be signifi­
cantly sup erio r in te rm s of close intensity o f 5-FU,
toxicity, response  ra te  and survival com pared to the
18sam e schedule  b u t g iven at a flat infusion rate. In 
this study a 5-FU p eak  delivery period (PDP) w ith  a 
m axim um  occurring  at 0 3 .0 0 -0 4 .0 0  h was used. 
O thers have sh o w n  that a PDP of 5-FU w ith  a 
m axim um  at 2 1 .0 0 - 2 2 . 0 0  h m ay allow a fu rther 2 0 %
19increase in the daily 5-FU dose. We perform ed a 
phase I study in p a tien ts  w ith  colorectal cancer w ith  
a schedu le  o f w eekly chronom odulated  48 h infusion 
of high-dose 5FU biochem ically m odulated by 
m eth o trexa te  (MTX) and LV The objectives o f our
allows a h igher dose in tensity  com pared  w ith  bolus study w ere  to d e te rm in e  the maximal tolerated dose 
adm inistration. Several clinical trials in patients w ith  (MTD) and the  op tim al PDP of 5-FU at this schedule, 
colorectal cancer have sh o w n  the  superiority  o f 
infusional versus bolus delivery o f 5-FU in term s o f
response rate, quality of life and cost-effectiveness; 
however, a survival benefit has nev er been dem on­
strated.
Circadian m echanism s relevant to the trea tm ent of 
cancer have been identified in roden ts and hum ans. 
These include 24 h changes in the activities o f 
several enzym es involved in 5-FU m etabolism , the  
pharm acokinetics o f 5-FU infusion, and the prolifera-
Patients and methods
Patients
i  itive activity
V - 10mucosa.
of bone and intestinalm arrow
Based on these  data it has been
hypothesized that circadian tim ing of d rug  delivery
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Inclusion criteria w e re  histologically proven adeno­
carcinom a of the  co lon  or rectum, measurable 
m etastatic  o r advanced disease w ith  a minimum 
d iam eter o f the largest lesion of 2  cm, disease not 
am enable to curative surgery, WHO perform ance 
status ^  2 , age 1 8 -7 5  years, norm al values for serum  
creatin ine and bilirubin, WBC ^  3*0 X l()9 /l, plate- 
^  1 0 0  X 1 0 9 /I, and w ritten  informed consent. 
Exclusion criteria w e re  previous radiotherapy on all 
disease param eters, clinical signs of CNS involve­
m ent, ev idence o f significant ascites or pleural fluid, 
previous second m alignancy w ith  the exception  of 
adequately  treated  in  s i tu  carcinom a of the cervix or
’A f L 1
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basal/squam ous cell carcinom a of the skin, serious 
active infections or o th e r concom itan t serious non- 
malignant disease and p reg n an cy  o r lactation. Institu­
tional board review  was obtained.
Results
T reatment
Treatm ent was ambulatory, and  consisted of MTX 
4 ()m g /m 2 i.v. bolus on  day I, followed 2 0 -2 4  h
later by LV (Isovorin011; Cyanamid, Iloofddorp, The 
Netherlands) 45 m g /d o se  orally every 6  h for eight 
doses and 5-FU infusion on  day 2. 5-FU was adm in­
istered as a continuous infusion for 48 h through a 
s.c. im planted venous p o r t system (Port-A-Cath; 
Pharmacia, W oerden, T he N etherlands) by a p ro ­
grammable in-time p u m p  (DeUec Cadd-Plus; Pharm a­
cia or Verifuse; NPBI, A m sterdam , The Netherlands). 
Patients w ere evaluated every cycle for toxicity and 
every 2  m onths for response. Toxicity and response 
w ere evaluated according to W HO criteria. The dose 
of 5-FU was increased in coho rts  o f th ree  patients. 
In case of grade ^  3 toxicity, a total o f six patien ts
Tw enty four patients en tered  the  study, 14 male and 
10 female. Median age was 6 1 years (range 43-71), 
median WHO perform ance status was 1 (0 -2 ), 
m edian serum  LDII value was 770 U /l (range 
161-2883, norm al values < 3 3 0  U /l) and median 
WBC was 8 . 6  X 1 0 y/l  (range 5 .0 -12 ,2). One patient 
w as excluded from the analysis because of 
disease progression after one cycle. Ten patients
had failed on previous systemic chemo­




The 5-FlI dose levels w ith corresponding PDP 
adm inistered to 23 patients is show n in Table 1. At a 
PDP of 0 .0 0 -6 .3 0  h the MTI) of 5-FU was 
2 6 0 0  m g /n r  /4 8  h, since of the three patients trea­
ted at 2800 m g /m 2/4 8  h, one patient experienced 
grade 3  stom atitis and diarrhea, and one patient
w ere treated at that particu lar 5-FU dose level. Dose- grade 3 vom iting and grade 4 diarrhea. The PDP was
limiting toxicity was defined as grade ^  3  toxicity in then  changed to 18 .00-0 .30  h and at this PDP dose-
tw o or m ore of six p a tien ts  during the first four limiting toxicity occurred  at 3 0 0 0  m g /m 2/4 8  h with 
evaluable weekly cycles. The MTD w as defined as all th ree  patients experiencing  grade 3 /4  toxicities 
the 5-FU dose at w hich  one o r less o f six patien ts (one patient grade 3 stom atitis and diarrhea, and
experienced reversible, to lerable and m anageable 
grade 3 toxicity, w hich  was im m ediately below  a 5-
tw o patients grade 3 and grade 4 stomatitis, respec­
tively). A 5-FU dose of 2800 m g /n r /4 8  h with a PDF 
FIJ dose that produced grade 5= 3 toxicity in tw o o r of 18 .00-0 .30  h could safely be administered. In 
m ore of six patients. T he  starting  dose of 5-FU was order to assure feasibility, 10 patients were even- 
2400 m g /m 2/4 8  h and this w as increased in steps o f tually treated at this 5-FU dose level and PDP, and 
2 0 0  m g /m 2 / 4 8  h in su b seq u en t cohorts  of patients. grade 3  vomiting and diarrhea occurred in only one 
The initial PDP of 5-FU w as 0 .0 0 -0 6 .3 0  h. During patient, and grade 2  stom atitis and diarrhea in nine 
this period 65% of the daily 5-FU dose w as delivered, and one patients, respectively. After the fourth cycle,
After reaching the MTD of 5-FU, subsequen t cohorts w hen  cycles w ere  adm inistered once every 2  weeks,
Table 1. Patients and occurrence of toxicity at the differ­
ent 5-FU dose levels
of three to six patients w ere  treated  at MTD but a further 5-FU dose escalation was performed in lour 
w ith a PDP from 1 8 .0 0 -0 .3 0  h and 5-FU dose was patients to 3500 m g /n r /4 8  h and this was possible 
increased according to  the  abovem en tioned  sche- w ithout an increase in toxicity, 
dule. Treatment cycles w ere  adm inistered  every 
w eek lor four consecutive w eeks and once every 2  
weeks thereafter until the  o ccu rren ce  of disease 
progression or unacceptable  toxicity.
In case of grade 5* 3 toxicity  trea tm en t w as w ith ­
held until values had re tu rn ed  to the  norm al range 
and/or symptoms had d isappeared . In case of 
recovery w ithin this period , the  dose o f 5-FU w as 
reduced to 75%. Doses o f MTX and LV w ere  no t 
reduced. In case of 5-FU dose reduction  due to 
toxicity occurring during  the  first four w eekly 
cycles, and in the absence  of grade ^  2  toxicity 
during subsequent tw o w eekly  cycles, it was recom ­
m ended to increase the 5-FlJ dose again to 100%,
5-FU dose 
(mg/m2/48 h)
PDP (h) Total no. of patients/ 
patients with grade
3/4 toxicity
2400 0.00- 6.30 3/0
2600 0.00 6.30 4/0
2600 0.00 6.30 3/2
2800 18.00 0.30 10/1
3000 18.00 0.30 3/3
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Tumor response LV and MTX are the  only biochem ical m odulators 
of 5-FU to date that have show n activity in rando­
mized clinical trials . 28,29 Furtherm ore, MTX effec­
tively modulates 5-FU w h en  given as a continuous 
infusion .21 Very few  data exist on clinical trials in 
response. O ne  previously  un trea ted  patient achieved w hich MTX and LV are bo th  adm inistered as biochem-
One pa tien t w as n o t evaluable for response due to 
w ithdraw al from  the  study after th ree  cycles because 
of toxicity. T herefore, 22 patients w ere evaluable for
a partial re sp o n se  o f 9 m on ths duration, the remain- ical modulators o f 5 -FU. Two small random ized trials
ing 21 pa tien ts  had  stable disease for a m edian have M e d  to show  a significant difference betw een
duration o f 8  (range 3 —2 0 + )  m onths. W ith a median 
follow-up of 1 0  m on ths, th e  m edian overall survival 
for all patien ts has n o t b e e n  reached.
treatm ent w ith  5-Fu/MTX/LV and 5-FU/LV. 30,31 In
Discussion
A schedule  o f w eek ly  flat-rate 5-FU infusion at
6 0  m g /k g /4 8  h  (equivalen t to 2400 m g /ir r /4 8  h) 
has been  described  by Shah et al.
most trials in w hich  5-FU is com bined w ith  bo th  MTX 
and LV, the  latter is used  as a rescue for MTX 
adm inistration . 29 From this meta-analysis, the authors 
could not exclude the possibility that the clinical 
benefit of MTX m odulation was due to theJLV rescue. 
In preclinical models the results of double m odula­
tion of 5-FU by MTX and LV are conflicting, although 
most studies failed to show  an advantage for double 
over single m odulation; Trim etrexate, a dihydro-
schedule has b een  u sed  in several clinical stud­
ies .21“" 25 T he  MTD o f chronom odulated  5-FU bio­
chem ically m odu la ted  by MTX and LV in our study 
was 2800 m g /m 2/4 8  h. The MTD of double m odu­
lated flat-rate 5-FU infusion given over 48 h has never 
been investigated. For com parison, the  MTD of 
weekly 48 h  flat-rate 5-FU infusion w ithout m odula­
tion w as 3500 m g /m 2 ,26 and of w eekly 24 h  5-FU
27infusion m odula ted  by  LV w as 2600 m g /m 2. Based 
on  these data, it seem s likely that a  5-FU dose of 
2800 m g /m 2/4 8  h  given at a flat rate will be too  toxic 
in com bination w ith  b o th  MTX and LY since double 
m odulation is likely to result in an increase in toxicity 
com pared  w ith  single or no  modulation, Although 
ou r study did n o t have th e  appropriate  design to 
allow a d irect com parison  w ith  a flat-rate infusion 
schedule, o u r results ap p ea r  to confirm earlier obser­
vations tha t ch ro n o m o d u la ted  delivery of 5-FlJ allows
folate reductase inhibitor w hich  does not com pete  
w ith  LV for cellular uptake and m etabolism , might 
therefore be a m ore suitable m odulator o f 5-FU in 
com bination w ith  LV.’^  Early results o f clinical trials 
w ith this com bination have been  prom ising.' ’*
We had one partial response in 12 patients 
previously not treated w ith  chem otherapy and no 
response in 10 p re treated  patients. A lthough this 
result is disappointing, it should be no ted  that 
patients rem ained stable for a substantial period of 
time (median of 8  m onths). Graf e t  a t have show n 
that in metastatic colorectal cancer patients treated 
w ith chem otherapy stabilization of disease is m ean­
ingful to the patients, since they found only a small 
difference (i.e. 2  m onths) in m edian survival be­
tw een patients w ith  disease stabilization and those 
w ho achieved a partial remission. The median 
survival in excess of 1 0  m onths in our patients of
a high 5-FU dose intensity. These data also suggest w hom  43% w ere  pretreated  w ith  ano ther 5-FU regi- 
tliat a 5-FLf dose o f 2400 m g /m 2/4 8  h w hich  has men may support this.
been used in a recen t random ized study was sub In conclusion, w e show ed that weekly d iro  nom o
optimal, as w as also ev idenced  by the  very low  inei- dulated 48 h infusion of 5-FU biochemically modu- 
dence of grade 3 /4  toxicity  in this study . 21 Further- lated by MTX and LV is feasible, and that the MTI) of 
more, in this last study the  same schedule o f four 5-FU in this schedule is 2800 m g /m 2. W ith this
schedule a PDP of 18.00 0,30 h is m odestly superior 
to a PDP of 0 .0 0 0 6 ,3 0  h. Based on ou r results as
weekly cycles follow ed by one cycle every 2  w eeks 
w as used, and although  this was not the prim ary 
objective in ou r study, w e  could increase the 5-FU 
dose of the  tw o-w eekly  cycles in fbur patients up  to 
3500 m g /m 2/4 8  h w ith o u t any increase in toxicity.
We found  that a PDP of 18 .00-0 .30  h. allowed a 
higher 5»FU dose in tensity  com pared  w ith a PDP 
o f 0 .0 0 - 6 . 3 0  h, b u t this difference was small
well as the results of recen t clinical trials, the use of 
double modulation of 5-FU by LV and MTX cannot 
be advocated.
(200 m g /m 2 /cyc le). B jarnason e t  a l V) also found in 
a schedule o f low-close 14 day infusion of 5-FU that a 
peak  infusion a ro u n d  2 1 .0 0 - 2 2 , 0 0  h was superior to 
a peak infusion around  0 3 .0 0 -0 4 .0 0  h.
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